Valuation: Novavax, Inc.

Capitalization 1.05B 912M 856M 779M 1.43B 90.76B 1.62B 10B 3.9B 41.47B 3.94B 3.86B 153B P/E ratio 2025 *
2.54x
P/E ratio 2026 * 20.7x
Enterprise value 672M 583M 547M 498M 914M 58.04B 1.03B 6.39B 2.49B 26.52B 2.52B 2.47B 97.53B EV / Sales 2025 *
0.66x
EV / Sales 2026 * 1.53x
Free-Float
94.79%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-7.68%
1 week-12.42%
Current month-11.58%
1 month-3.57%
3 months-22.55%
6 months-29.69%
Current year-19.28%
More quotes
1 week 6.46
Extreme 6.455
7.8
1 month 6.46
Extreme 6.455
8.78
Current year 5.01
Extreme 5.01
11.55
1 year 5.01
Extreme 5.01
17.81
3 years 3.53
Extreme 3.5324
76.77
5 years 3.53
Extreme 3.5324
331.68
10 years 3.53
Extreme 3.5324
331.68
More quotes
Manager TitleAgeSince
Chief Executive Officer 58 2023-01-22
Director of Finance/CFO 59 2021-08-15
Director of Finance/CFO 65 2021-04-11
Director TitleAgeSince
Director/Board Member 72 2010-08-05
Director/Board Member 65 2018-10-31
Director/Board Member 59 2020-06-15
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-7.68%-12.42%-53.81%-82.77% 1.05B
-0.20%-2.91%+18.40%+14.81% 48.55B
+30.00%+363.16%+72,525.70%+6,614.30% 38.57B
-3.23%-0.03%-27.76%-21.56% 26.66B
+0.62%+3.17%-3.66%+20.89% 26.1B
+0.23%+3.83%+15.51%-20.34% 12.55B
-2.62%+4.74%+92.19% - 12.14B
-3.52%+1.54%-55.16%-28.10% 11.27B
-2.71%-0.14%+38.78%+119.97% 10.44B
-1.90%+0.82%+3.49%+0.83% 10.08B
Average -1.93%+37.79%+7,255.37%+735.34% 19.74B
Weighted average by Cap. -0.99%+73.84%+14,175.13%+1,383.86%
See all sector performances

Financials

2025 *2026 *
Net sales 1.02B 887M 833M 758M 1.39B 88.31B 1.57B 9.73B 3.8B 40.35B 3.84B 3.76B 148B 527M 458M 429M 391M 717M 45.53B 811M 5.01B 1.96B 20.8B 1.98B 1.94B 76.5B
Net income 494M 429M 402M 366M 672M 42.66B 760M 4.7B 1.83B 19.49B 1.85B 1.81B 71.69B 60.4M 52.41M 49.19M 44.74M 82.12M 5.22B 92.88M 574M 224M 2.38B 227M 222M 8.76B
Net Debt -379M -329M -309M -281M -515M -32.72B -583M -3.6B -1.41B -14.95B -1.42B -1.39B -54.99B -246M -213M -200M -182M -334M -21.24B -378M -2.34B -913M -9.7B -923M -904M -35.69B
More financial data * Estimated data
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Employees
952
More about the company
Date Price Change Volume
25-06-17 6.490 $ -7.68% 8,763,585
25-06-16 7.030 $ +1.30% 4,590,283
25-06-13 6.940 $ -2.94% 5,179,634
25-06-12 7.150 $ +0.85% 4,000,736
25-06-11 7.090 $ -1.53% 5,975,769

Delayed Quote Nasdaq, June 17, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
6.490USD
Average target price
13.43USD
Spread / Average Target
+106.91%
Consensus

Quarterly revenue - Rate of surprise